Eli Lilly and Company (LLY)
Automate Your Wheel Strategy on LLY
With Tiblio's Option Bot, you can configure your own wheel strategy including LLY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LLY
- Rev/Share 66.2502
- Book/Share 26.5925
- PB 41.7334
- Debt/Equity 1.7865
- CurrentRatio 1.5463
- ROIC 0.286
- MktCap 992485244666.0
- FreeCF/Share 10.0576
- PFCF 110.0231
- PE 53.9306
- Debt/Assets 0.3698
- DivYield 0.0054
- ROE 1.0226
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | LLY | UBS | -- | Buy | -- | $1250 | Jan. 7, 2026 |
| Upgrade | LLY | Daiwa Securities | Neutral | Buy | -- | $1230 | Dec. 16, 2025 |
| Reiterated | LLY | BofA Securities | -- | Buy | $1286 | $1268 | Dec. 15, 2025 |
| Reiterated | LLY | Goldman | -- | Buy | $951 | $1145 | Dec. 15, 2025 |
| Initiation | LLY | Scotiabank | -- | Sector Outperform | -- | $1165 | Nov. 13, 2025 |
| Upgrade | LLY | Leerink Partners | Market Perform | Outperform | -- | $1104 | Nov. 10, 2025 |
| Reiterated | LLY | BMO Capital Markets | -- | Outperform | $840 | $930 | Oct. 20, 2025 |
| Upgrade | LLY | Erste Group | Hold | Buy | -- | -- | Oct. 14, 2025 |
| Downgrade | LLY | Berenberg | Buy | Hold | -- | $830 | Sept. 17, 2025 |
| Upgrade | LLY | HSBC Securities | Reduce | Hold | -- | $700 | Aug. 27, 2025 |
News
My Top 5 Biotech Stocks Big Pharma Could Buy Next
Published: October 06, 2025 by: Seeking Alpha
Sentiment: Positive
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their portfolios of drugs.
Read More
"Exciting Race" Between LLY & NVO, Tariffs Remain Long-Term Overhang
Published: October 06, 2025 by: Schwab Network
Sentiment: Neutral
Lee Brown sees lots of potential in the weight loss drug space, noting Eli Lilly (LLY) and Novo Nordisk (NVO) as the two companies he expects to lead. He points to "incredible" discounts and expanded access to GLP-1s as indicators these companies will see wider moats for their products.
Read More
Top 50 High-Quality Dividend Growth Stocks For October 2025
Published: October 03, 2025 by: Seeking Alpha
Sentiment: Positive
I track a universe of 50 high-quality dividend growth stocks to identify opportune investments based on valuation and future return potential. As of October 2, 2025, 22 stocks offer attractive future return estimates of at least 10%, with 15 appearing potentially undervalued by my Free Cash Flow model. Top-ranked stocks include MKTX, RMD, MPWR, RACE, and MSCI, each offering strong projected returns driven by yield, valuation upside, and EPS growth.
Read More
Kernal Bio Joins Lilly Gateway Labs to Accelerate In Vivo Cell Therapies
Published: October 03, 2025 by: Business Wire
Sentiment: Neutral
BOSTON--(BUSINESS WIRE)-- #AI--Kernal Bio retains strategic independence, while gaining access to shared resources, operational support and Lilly's global network of experts.
Read More
Buy LLY Stock At $820?
Published: October 03, 2025 by: Forbes
Sentiment: Positive
The entire pharmaceutical sector is experiencing a rerating this week, as investors realize the adverse impact of tariffs and drug price cuts won't be as severe as previously anticipated. While most major pharma stocks have rallied, Eli Lilly stock (NYSE: LLY) warrants particular attention.
Read More
How I Would Build An Ultra-High-Conviction Retirement Portfolio Right Now
Published: October 03, 2025 by: Seeking Alpha
Sentiment: Neutral
Building a resilient retirement portfolio requires a mix of disruption-proof income from REITs, midstream energy, and high-yielding assets, plus growth stocks and ETFs. Current market challenges—AI disruption, weak job market, inflation risks—make long-term planning difficult, but also highlight the need for self-reliance and diversification. Core portfolio holdings should include large, proven REITs, natural gas midstream companies, select high-yield stocks, BDCs, preferred equity ETFs, and actively managed income funds.
Read More
Why Eli Lilly Is The Lion's Share Of My Portfolio
Published: October 02, 2025 by: Seeking Alpha
Sentiment: Positive
Healthcare is underowned; 2026 rate cuts and policy clarity should trigger inflows. As XLV's largest weight and obesity leader, Lilly will capture outsized demand during the sector re-rating cycle. Orforglipron, first true oral GLP-1, solves compliance issues and expands TAM. LLY's $1B pre-launch inventory and $15B+ capex signal FDA approval certainty and industrialized pill-based obesity treatment scale. Diversified growth via Alzheimer's, immunology, and oncology pipelines, backed by disciplined governance and supply-first execution. Supports long-term compounding and >40% 12-month upside from $830, with re-rating potential toward ~35× P/E.
Read More
Another Surging Pharma Stock to Watch Right Now
Published: October 01, 2025 by: Schaeffers Research
Sentiment: Positive
Pharmaceutical concern Eli Lilly And Co (NYSE:LLY ) is charging 7.2% higher to trade at $821.20 this afternoon.
Read More
Top Stock Movers Now: Nike, Eli Lilly, Corteva, AES, and More
Published: October 01, 2025 by: Investopedia
Sentiment: Negative
The S&P 500, Dow, and Nasdaq were little changed Wednesday afternoon, as a federal government shutdown took effect.
Read More
Is Lilly (LLY) a Buy as Wall Street Analysts Look Optimistic?
Published: September 30, 2025 by: Zacks Investment Research
Sentiment: Positive
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Read More
3 Growth Stocks to Invest $1,000 Right Now
Published: September 29, 2025 by: The Motley Fool
Sentiment: Positive
Those who succeed at building wealth in the stock market often do so by buying and holding stakes in companies that have the ability to expand steadily over time. Such companies can frequently be found in the technology and healthcare sectors -- two sources of innovations that sometimes reshape our lives.
Read More
Eli Lilly: Strong Buy On Sustained Growth, Expanding Moat, And Pipeline Depth
Published: September 29, 2025 by: Seeking Alpha
Sentiment: Positive
Eli Lilly's valuation has compressed significantly from last year's highs, despite fundamentals improving faster than its share price. Industry-leading incretin treatments (Mounjaro, Zepbound) are driving rapid revenue growth, with market share gains over Novo Nordisk. Capacity expansion, U.S.-based manufacturing, and price reductions are improving accessibility while sustaining margins.
Read More
LLY Stock Set For A 20% Breakout?
Published: September 29, 2025 by: Forbes
Sentiment: Positive
Eli Lilly stock (NYSE: LLY) should be on your radar. Here's why – it is presently trading within the support range ($688 – $761), price points from which it has previously bounced significantly.
Read More
A New Prescription For Pain: Understanding Trump's 100% Pharma Tariff
Published: September 26, 2025 by: Seeking Alpha
Sentiment: Negative
Novo Nordisk, Sanofi, and AstraZeneca face the largest dollar exposure to President Trump's new 100% tariff on imported branded drugs. NVO's heavy reliance on U.S. sales and imported GLP-1 products puts over 50% of its free cash flow at risk, despite ongoing U.S. manufacturing expansion. Sanofi's high-margin Dupixent and AZN's broad U.S. portfolio are also vulnerable, though both are investing in U.S. production to seek exemptions.
Read More
LLY Gets EU Approval for Alzheimer's Drug & FDA Nod to Cancer Therapy
Published: September 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Eli Lilly secures EU approval for Alzheimer's drug Kisunla and gains FDA nod to breast cancer therapy Inluriyo.
Read More
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock
Published: September 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Read More
US FDA approves Eli Lilly's therapy for metastatic breast cancer
Published: September 25, 2025 by: Reuters
Sentiment: Positive
Eli Lilly said on Thursday that the U.S. Food and Drug Administration has approved its therapy for the treatment of metastatic breast cancer in patients whose disease progressed after at least one line of endocrine therapy.
Read More
U.S. FDA approves Inluriyo (imlunestrant) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
Published: September 25, 2025 by: PRNewsWire
Sentiment: Neutral
An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor In the Phase 3 EMBER-3 trial, Inluriyo monotherapy reduced the risk of progression or death by 38% versus endocrine therapy among patients with ESR1-mutated MBC INDIANAPOLIS , Sept. 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Inluriyo (imlunestrant, 200 mg tablets), an oral estrogen receptor antagonist, for the treatment of adults with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2–), …
Read More
Eli Lilly and Company (LLY) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript
Published: September 25, 2025 by: Seeking Alpha
Sentiment: Neutral
Eli Lilly and Company (NYSE:LLY ) Bernstein 2nd Annual Global Healthcare Conference September 25, 2025 8:00 AM EDT Company Participants Lucas Montarce - Executive VP & CFO Mike Czapar - Director of Investor Relations Conference Call Participants Courtney Breen - Sanford C. Bernstein & Co., LLC.
Read More
Eli Lilly: Buying The Dip With Confidence
Published: September 25, 2025 by: Seeking Alpha
Sentiment: Positive
Eli Lilly (LLY) remains a strong growth company, driven by leadership in the booming GLP-1 and diabetes drug markets despite recent share price weakness. LLY's aggressive investments in manufacturing, superior clinical trial results, and AI-driven drug discovery reinforce its competitive edge and future revenue potential. Valuation is set to improve as earnings are projected to surge, making LLY's current high P/E attractive for long-term investors seeking growth.
Read More
LLY vs. NVO: Which Obesity Drug Stock Is the Better Buy Now?
Published: September 24, 2025 by: Zacks Investment Research
Sentiment: Neutral
Eli Lilly's diversified pipeline, rapid tirzepatide growth and rising estimates give it the edge over Novo Nordisk in the obesity drug battle.
Read More
2 stocks to reach $1 trillion market cap in 2026
Published: September 24, 2025 by: Finbold
Sentiment: Neutral
Amid the ongoing United States stock market rally, several equities have experienced increased buying pressure, pushing their valuations closer to the coveted $1 trillion market capitalization mark.
Read More
Eli Lilly to Build $6.5 Billion Ingredient-Manufacturing Facility in Texas
Published: September 23, 2025 by: WSJ
Sentiment: Positive
The planned site, which will be used to manufacture the company's first oral weight-loss drug, is expected to be operational within five years.
Read More
Eli Lilly to make weight-loss pill in new $6.5 billion Texas plant
Published: September 23, 2025 by: Reuters
Sentiment: Positive
Eli Lilly will make its next-generation experimental weight-loss pill, orforglipron, at a new multi-billion-dollar manufacturing plant it plans to build in Texas, the company said on Tuesday.
Read More
Eli Lilly to build $6.5 billion Texas manufacturing facility for obesity pill, other drugs
Published: September 23, 2025 by: CNBC
Sentiment: Positive
Eli Lilly said it will spend $6.5 billion to build a manufacturing facility in Houston, Texas, to boost production of the company's pipeline of small molecule drugs, including its closely watched experimental obesity pill. It is the second in a string of four new planned U.S. plants by the drugmaker, which will all begin making medicine within five years.
Read More
Lilly plans to build a new $6.5 billion facility to manufacture active pharmaceutical ingredients in Texas
Published: September 23, 2025 by: PRNewsWire
Sentiment: Neutral
The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines Company plans to create 4,615 manufacturing and construction jobs INDIANAPOLIS , Sept. 23, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it plans to build a new $6.5 billion manufacturing facility at Generation Park in Houston, Texas.
Read More
Mounjaro, Ozempic: Obesity market shifting to portfolio play as GLP-1 innovation peaks, says leading bank
Published: September 23, 2025 by: Proactive Investors
Sentiment: Positive
Goldman Sachs analysts say the obesity drug market is entering a new phase where breadth of treatment options, rather than reliance on a single blockbuster, will determine long-term winners. Wrapping up last week's European Association for the Study of Diabetes (EASD) meeting, the bank highlighted three key trends.
Read More
This Unstoppable Healthcare Stock Just Made a Move in AI: Time to Buy?
Published: September 19, 2025 by: The Motley Fool
Sentiment: Positive
Recent breakthroughs in artificial intelligence (AI) are producing tangible results, and not just in the tech industry, although companies in that sector tend to dominate the AI headlines. Even in healthcare, the technology can help boost productivity and efficiency.
Read More
Eli Lilly's Oral GLP-1 Breakthrough Could Change Everything
Published: September 18, 2025 by: MarketBeat
Sentiment: Positive
Eli Lilly and Company NYSE: LLY has been one of the best-performing stocks outside of the AI-enhanced Magnificent 7 stocks over the past 12 months. The company is the leader in the GLP-1 market, which is transforming the management of type 2 diabetes and the obesity market.
Read More
LLY's Orforglipron Tops NVO's Oral Pill in Diabetes Study: What's Next?
Published: September 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Eli Lilly's orforglipron beat NVO's Rybelsus in a 52-week diabetes study, showing stronger A1C and weight loss benefits.
Read More
About Eli Lilly and Company (LLY)
- IPO Date 1972-06-01
- Website https://www.lilly.com
- Industry Drug Manufacturers - General
- CEO David A. Ricks
- Employees 47000